Headache Group, Wolfson CARD, Institute of Psychiatry, Psychology and Neuroscience, King's College London, and National Institute for Health Research (NIHR) SLaM Clinical Research Facility at King's, Wellcome Foundation Building, King's College Hospital, London, SE5 9PJ, UK.
Department of Neurology, Hospital Garcia de Orta, Almada, Portugal.
J Neurol. 2023 Jul;270(7):3654-3666. doi: 10.1007/s00415-023-11706-1. Epub 2023 Apr 8.
Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and peripheral nervous system areas and networks. A growing increase in the understanding of migraine pathophysiology in recent years has facilitated translation of that knowledge into novel treatments, which are currently becoming available to patients in many parts of the world and are substantially changing the clinical approach to the disease. In the first part of this review, we will provide an up to date overview of migraine pathophysiology by analyzing the anatomy and function of the main regions involved in the disease, focusing on how these give rise to the plethora of symptoms characterizing the attacks and overall disease. The second part of the paper will discuss the novel therapeutic agents that have emerged for the treatment of migraine, including molecules targeting calcitonin gene-related peptide (gepants and monoclonal antibodies), serotonin 5-HT receptor agonists (ditans) and non-invasive neuromodulation, as well as providing a brief overview of new evidence for classic migraine treatments.
偏头痛是一种极其致残、常见的神经系统疾病,其特征为复杂的神经生物学,涉及一系列中枢和外周神经系统区域和网络。近年来,人们对偏头痛病理生理学的认识不断加深,这促进了将这些知识转化为新的治疗方法,目前这些治疗方法已在世界许多地区的患者中得到应用,并正在极大地改变对该疾病的临床治疗方法。在这篇综述的第一部分,我们将通过分析参与该疾病的主要区域的解剖结构和功能,对偏头痛病理生理学进行最新概述,重点讨论这些区域如何导致发作和整体疾病的众多症状。本文的第二部分将讨论用于偏头痛治疗的新型治疗药物,包括靶向降钙素基因相关肽的分子(降钙素基因相关肽、单克隆抗体)、血清素 5-HT 受体激动剂(二坦)和非侵入性神经调节,以及简要概述经典偏头痛治疗的新证据。